Products SCH 56592 + SCH 56592 + SCH 56592 + SCH 56592 + Terbinafine + Placebo
SCH 56592 + SCH 56592 + SCH 56592 + SCH 56592 + Terbinafine + Placebo Phase 2 Completed ⚡ Active Jun 1, 2007 → Dec 1, 2008
About SCH 56592 + SCH 56592 + SCH 56592 + SCH 56592 + Terbinafine + Placebo SCH 56592 + SCH 56592 + SCH 56592 + SCH 56592 + Terbinafine + Placebo is a phase 2 stage product being developed by Merck for Onychomycosis. The current trial status is completed. This product is registered under clinical trial identifier NCT00491764. Target conditions include Onychomycosis.
Clinical Trials (1) NCT ID Phase Status Start Completion Indication NCT00491764 Phase 2 Completed Jun 1, 2007 Dec 1, 2008 Onychomycosis
Product Company Stage Hype Score NVXT Solution + Vehicle of test product Sun Pharmaceutical Phase 2 NVXT topical + Placebo (Vehicle) Topical Sun Pharmaceutical Phase 2 terbinafine + Placebo + terbinafine + Placebo Novartis Phase 3 terbinafine hydrogen chloride + amorolfine nail lacquer Novartis Phase 3 terbinafine + Placebo + terbinafine + Placebo Novartis Phase 3 AN2690 Pfizer Phase 2 AN2690, 2.5% + AN2690, 5% + AN2690, 7.5% + Vehicle Pfizer Phase 2 AN2690 Solution, 5.0% + AN2690 Solution, 7.5% Pfizer Phase 2 AN2690 Topical Solution, 5% + Solution Vehicle Pfizer Phase 3 AN2690 + AN2690 Pfizer Phase 2 Tavaborole 5% Topical Solution Pfizer Approved AN2690 Solution, 5.0% Pfizer Phase 2 AN2690, 2.5% + AN2690, 5% + AN2690, 7.5% + AN2690 Solution Vehicle Pfizer Phase 2 AN2690 Pfizer Phase 2 AN2690 Topical Solution, 5% + Solution Vehicle Pfizer Phase 3 AN2690 + AN2690 + AN2690 Pfizer Phase 1 Albaconozole + Placebo + Albaconozole + Placebo + Albaconozole + Placebo GSK plc Phase 1 Itraconazole 100mg capsules + Itraconazole 200mg tablets + Placebo tablets GSK plc Phase 3 Albaconazole tablet 400mg + Albaconazole 100mg capsules, then albaconazole 400mg tablet GSK plc Phase 1 Albaconazole 100mg + Albaconazole 200mg + Albaconazole 400mg + Albaconazole 400mg + Placebo 400 mg GSK plc Phase 2
Other Products from Merck